Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2019-03-29 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
平安证券股份有限公司关于公司2018年募集资金存放与实际使用情况的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Ping An Securities regarding the verification of the storage and actual use of funds raised by Pulike Bioengineering Co., Ltd. in 2018. It includes specific financial figures about the amount raised, usage of funds, management of funds, changes in investment projects, and compliance with regulatory requirements. The content focuses on the management and use of raised capital, including investment projects and cash management, which aligns with the characteristics of a Capital/Financing Update. The document is over 6,000 characters and contains substantive financial data and analysis related to fundraising and capital usage, not merely an announcement or certification. Therefore, it fits best under the Capital/Financing Update (CAP) category.
2019-03-29 Chinese
关于对部分暂时闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the management of temporarily idle funds through cash management products. It details the board's approval, risk control measures, and opinions from independent directors and the supervisory board. The document is relatively short (1509 characters) and focuses on a specific financial management decision rather than presenting comprehensive financial data or results. It does not contain financial statements or detailed financial analysis. This type of announcement fits best under Capital/Financing Update (CAP), as it relates to the company's management of its capital resources and investment activities.
2019-03-29 Chinese
北京德恒律师事务所关于普莱柯生物工程股份有限公司回购注销部分限制性股票事宜的法律意见
Transaction in Own Shares Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the repurchase and cancellation of restricted shares by a company. It discusses the legal compliance, approval, and authorization related to the stock repurchase under the company's stock incentive plan. The document is not a financial report, earnings release, or management discussion but a legal opinion specifically about a share repurchase transaction. This fits the category of Transaction in Own Shares (POS), which covers reports of the company buying back or selling its own shares. The document length is 3307 characters, which is consistent with a detailed legal opinion rather than a brief announcement or a full financial report. Therefore, the correct classification is POS with high confidence.
2019-03-29 Chinese
关于聘任副总经理的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a new deputy general manager (副总经理) at the company 普莱柯生物工程股份有限公司. It includes details about the board meeting resolution, the individual's qualifications, and a brief resume. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no reference to any report publication. The content clearly relates to a change in senior management personnel. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is short and focused solely on management appointment, confirming the classification as MANG with high confidence.
2019-03-29 Chinese
关于对暂时闲置募集资金进行现金管理的实施公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 普莱柯生物工程股份有限公司 regarding the use of temporarily idle raised funds for cash management through structured deposits with a bank. It details the amounts, terms, expected returns, risk control measures, and impact on company operations. The document is relatively short (3218 characters) and focuses on a specific financing activity related to the management of idle raised funds, not a full financial report or earnings release. It is not an annual or interim report, nor a call transcript or AGM material. It is a specific update on capital management activities, fitting the Capital/Financing Update category.
2019-03-26 Chinese
关于对暂时闲置募集资金进行现金管理的实施公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 普莱柯生物工程股份有限公司 regarding the use of temporarily idle raised funds for cash management through purchasing structured deposit products. It details the amounts, terms, risk control measures, and impact on company operations. The document is relatively short (2518 characters) and focuses on a specific financing activity related to the management of idle raised funds, not a full financial report or audit. It does not contain comprehensive financial statements or quarterly/yearly results. It is not a report publication announcement since it contains substantive information about the cash management activity itself. Therefore, the document fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2019-03-04 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.